healthcare
Auto Added by WPeMatico
Birth control delivery startup Nurx taps Clover Health’s Varsha Rao as CEO
Varsha Rao, Airbnb’s former head of global operations and, most recently, the chief operating officer at Clover Health, has joined Nurx as its chief executive officer.
Rao replaces Hans Gangeskar, Nurx’s co-founder and CEO since 2014, who will stay on as a board member.
Nurx, which sells birth control, PrEP, the once-daily pill that reduces the risk of getting HIV, and an HPV testing kit direct to consumer, has grown 250 percent in the last year, doubled its employee headcount and attracted 200,000 customers. Rao tells TechCrunch the startup realized they needed talent in the C-suite that had experienced this kind of growth.
“The company has made some really great progress in bringing on strong leaders and that’s one of the things that got me excited about joining,” Rao told TechCrunch. Nurx recently hired Jonathan Czaja, Stitch Fix’s former vice president of operations, as COO, and Dave Fong, who previously oversaw corporate pharmacy services at Safeway, as vice president of pharmacy.
Rao, for her part, joined Clover Health, a Medicare Advantage startup backed by Alphabet, in late 2017 after three years at Airbnb.
“After being at Airbnb, a really mission-driven company, I couldn’t go back to something that wasn’t equally or more so and healthcare really inspired me,” Rao said. “In terms of accessibility, I feel like [Nurx] is super important. We are really fortunate to live in a place where can access birth control and it can be more easily found but there are lots of parts of the country where physical access is challenging and costs can be a factor. To be able to break down barriers of access both physically and from an economic standpoint is hugely meaningful to me.”
Nurx, a graduate of Y Combinator, has raised about $42 million in venture capital funding from Kleiner Perkins, Union Square Ventures, Lowercase Capital and others. It launched in 2015 to facilitate women’s access to birth control across the U.S. with a HIPAA-compliant web platform and mobile application that delivers contraceptives directly to customers’ doorsteps.
Today, the telehealth startup is available to customers in 24 states and counts Chelsea Clinton as a board member.
Powered by WPeMatico
Public health startup Cityblock raises $65M Series B
Redpoint Ventures has led a $65 million Series B in Cityblock, a healthcare company focused on providing improved care to low-income neighborhoods.
The business launched roughly 18 months ago out of Alphabet’s Sidewalk Labs, an urban innovation incubator known for projects like mobility data startup Coord, which itself raised a $5 million round in October.
“We’re a tech-enabled services company focused on caring for a population that has been traditionally overlooked by the innovation community and generally underserved across healthcare,” co-founder and chief executive officer Iyah Romm told TechCrunch. “We believe we can fundamentally redefine the way that health services are built across the country for low-income populations. These are populations that have never been prioritized.”
Romm has spent his entire career in the public health sector. Prior to joining Sidewalk Labs as an entrepreneur-in-residence in 2017, he spent one year as the chief transformation officer of the Commonwealth Care Alliance, a nonprofit medical care delivery organization.
Cityblock provides personalized medical and behavioral health and social services across a growing number of clinics on the East Coast. The company will use the investment to open additional clinics and continue the development of its core platform, Commons. The care delivery platform helps care workers collaborate and stay up to date on patients, with real-time hospital admission alerts to tools for tracking treatment progress.
Cityblock opened its first clinic, or “neighborhood hub,” in Brooklyn, New York after forging a partnership with EmblemHealth, a New York neighborhood health insurance business. They’ve since expanded to Connecticut via a partnership with ConnectiCare, a Connecticut insurance provider. Cityblock will open clinics in North Carolina later this year. Cityblock’s services come at no additional costs to members covered by partner insurance businesses.
The startup’s hope is to get these low-income demographics regular access to more affordable care. Preventative care, after all, is a whole lot cheaper than emergency room visits.
“People end up going to the ER when problems are really bad, for conditions that can be managed,” Redpoint partner and newly appointed Cityblock board member Elliot Geidt told TechCrunch. “There are 75 million people on Medicaid alone and a good portion of these people are living in the inner cities. It’s a problem that has a scope larger than most things that we see in the venture community. The big problem with this population is the existing healthcare system doesn’t work for them, it falls short on so many levels.”
New investors 8VC, Echo Health Ventures and StartUp Health also participated in the latest round, as did existing investors including Sidewalk Labs, Thrive Capital, Maverick Ventures, Town Hall Ventures and EmblemHealth.
Powered by WPeMatico
Bringing affiliate marketing and outsourced customer acquisition to Brazil nets Escale $22.6 million
Despite not being Brazilian and having their first exposure to the country only a few years ago, the two co-founders of Escale have managed to raise $22.6 million for their company, which provides customer acquisition services to companies in telecommunications and healthcare across Brazil.
Their secret? A knowledge of search engine optimization technologies honed through side businesses the two ran back in the United States.
The state of online marketing and digital sales was so woefully bad in Brazil that co-founders Matthew Kligerman and Ken Diamond had a green field in front of them on which to build Brazil’s first true online customer acquisition service, according to Diamond.
“We fell in love with Brazil for its warm culture and natural beauty, but as consumers, we had terrible experiences acquiring the most fundamental products and services for our new lives: internet, cell phone plans, health insurance and basic banking needs,” Kligerman said in a statement.
The company’s largest customer, according to Diamond, is NET, the Brazilian cable and telecom operator. NET was the first company to sign on for Escale’s customer acquisition services, but the company’s roster of clients now includes some of Brazil’s largest companies, including Bradesco, Sul America, Claro, GNDI and Amil.
It’s that marquee client list that attracted QED Investors and Invus Opportunities to co-lead the $22.6 million round that Escale just closed. The company’s previous investors, Kaszek Ventures, Rocket Internet’s GFC and Redpoint e.Ventures, also participated in the funding.
Latin America is in the throes of a startup renaissance at the moment, with Brazilian companies like Nubank and iFood and the Colombian company Rappi reaching billion-dollar valuations. Meanwhile investors are committing more capital to the region. SoftBank, for instance, is committing $5 billion to a new Latin American-focused fund.
With the new funding, Escale intends to move deeper into the development of customer acquisition platforms across verticals like consumer finance, insurance and education with comparison shopping sites and informational services (à la Credit Karma in the U.S.).
“With millions of web and cloud voice interactions every month, Escale can transform each of those interactions into data points, and continually improve its proprietary acquisition platform, ‘EscaleOS,’ to create highly-intelligent, customized marketing and sales funnels, helping consumers at the right moment connect with the products and services they need,” says Nicolas Berman, a partner at Kaszek Ventures. “The more consumer interactions they have, the faster Escale’s data flywheel spins.”
Powered by WPeMatico
Jio Health combines online and offline healthcare in Southeast Asia, starting in Vietnam
The internet is often lauded for the potential to increase the impact of a range of primary services in emerging markets, including education, commerce, banking and healthcare. While many of those platforms are now being built, a few are finding that a hybrid approach combining online and offline is advantageous.
That’s exactly what Jio Health, a “full stack” (forgive the phrase) healthcare startup is bringing to consumers in Southeast Asia, starting in Vietnam.
The company started as a U.S.-based venture that worked with healthcare providers around the “Obamacare” initiative, before sensing the opportunity overseas and relocating to Vietnam, the Southeast Asian market of 95 million people and a fast-growing young population.
Today, it operates an online healthcare app and a physical facility in Saigon; it also has licenses for prescriptions and over the counter drug sales. The serviced launched nearly a year ago; already the company has some 130 staff, including 70 caregivers — including doctors — and a tech team of 30.
The idea is to offer services digitally, but also provide a physical location for when it is needed. Therein, the company ensures that “every element of that journey” is controlled and of the required standard; that’s in contrast to services that partner with hospitals or other care centers.
The scope of Jio Health’s services range from pediatrics to primary care, chronic disease management and ancillary services, which will soon cover areas like eye care, dermatology and cancer.
“Our initial research [before moving] found that healthcare in Vietnam was unlike the U.S.,” Raghu Rai, founder and CEO of Jio Health, told TechCrunch in an interview. “Spending is primarily driven by the consumer (out of pocket) and there’s no real digital infrastructure to speak of.”
Rai — a U.S. citizen — said doctors typically “have minutes per patient” and get through “hundreds” of consultations in every morning shift. That gave him an idea to make things more efficient.
“We can probably address north of 80 percent of consumers’ health needs,” he said of Jio Health,” but we also have referral partnerships with certain hospitals.”
Raghu Rai is CEO and founder of Jio Health
The process begins when a consumer downloads the Jio Health app and inputs primary information. A representative is then dispatched to visit the consumer in person, potentially within “hours” of the submission of information, according to Rai.
He believes that Jio Health can save its users money and time by using remote consultancy for many diagnoses. The company also works with health insurance companies for areas like annual checkups, and Rai said that McDonald’s and 7-Eleven are among the corporations that offer Jio Health among the providers for their staff; they’re not exclusive.
This week, Jio Health announced that it has closed a $5 million Series A funding from Southeast Asia’s Monk’s Hill Ventures . Rai said the company plans to use the capital for expansion. In particular, he said, the company is adding new care categories this month — including eye care and dermatology — and it is working toward expanding its brand through marketing.
Further down the line, Rai said the company hopes to expand to Hanoi before the end of this year. While there is interest in moving into other markets within Southeast Asia, that isn’t about to happen soon.
“We have begun to investigate other markets, but at this point feel the market in Vietnam is substantial in itself,” he told TechCrunch. “It’s very plausible that we’d be looking at international expansion plans in 2020… we’re going to be focused on Southeast Asia.”
Powered by WPeMatico
Two Chairs nabs $7M for its client-therapist matching app and brick-and-mortar clinics
The future of healthcare isn’t entirely digital. For encounters as intimate as the client-therapist dynamic, a face-to-face relationship is still key.
For those able to afford tech-enabled therapy services, Two Chairs, a San Francisco-headquartered mental healthcare business, may be of interest. The startup believes in the power of in-person therapy, as opposed to the new variety of affordable digital tools meant to replace or coexist with therapy services. Today, the company is announcing a $7 million Maveron-led Series A financing to open additional brick-and-mortar clinics and build out its client-therapist matching app, which leverages technology to pair its customers with a therapist best-tailored to their needs.
The company currently operates four clinics in the Bay Area, where patients can access individual or group therapy. Each of those clinics was built with modern, young professionals in mind using “thoughtful design” to create “non-judgmental spaces.”
A Two Chairs clinic, which emphasizes “non-judgmental” design
The app and clinic interior design are the key differences between Two Chairs and a neighborhood private practice, it says. As far as pricing, at $180 an hour, a session doesn’t differ terribly from a typical session at a Bay Area private practice. The startup currently employs 30 therapists, who also are available over video chat should a client be sick or traveling, with a customer base of “several thousand.”
Two Chairs was founded in 2017 by former Palantir employee Alex Katz (pictured). In a conversation with TechCrunch, Katz admitted procuring real estate for Two Chairs’ brick-and-mortar clinics has been an expensive and difficult endeavor. It’s no wonder venture capitalists tend to favor IT startups devoid of the overhead costs associated with firms in the real estate business. Katz is hoping the latest investment, which brings Two Chairs’ total raised to $8 million, will help the business quickly sign additional leases outside of the most expensive city in the U.S.
The cash will also be used to advance Two Chairs’ matching app. The app surveys potential clients on their history, preferences and goals, then uses a library of data to match the client with the most suitable therapist in its roster and to create a customized treatment plan. Katz says they’ve provided clients with an accurate match 95 percent of the time.
“We know that the client-therapist relationship is the best predictor of an outcome with care and while it sounds intuitive, matching is not a concept that has existed in the mental health field historically,” Katz told TechCrunch.
Two Chairs is one of several mental health startups to capture the attention of venture capitalists lately. Basis, which helps people cope with anxiety and depression through guided conversations via chat and video, emerged from stealth in 2018 with a $3.75 million investment led by Bedrock. Wisdo, a community-focused app that connects people seeking help with those who can offer help, brought in an $11 million investment in December and emotional well-being app Aura raised $2.7 million from Cowboy Ventures in October.
Those three businesses have one thing in common: they are digital-first endeavors looking to innovate on top of a broken mental healthcare model. Two Chairs’ plan to build additional therapy clinics, however, doesn’t feel particularly inventive. Opening a chain of therapy offices, rather, sounds like a hard-to-scale, expensive business idea.
As for the uptick in capital for mental health tech, Katz is satisfied Silicon Valley has finally acknowledged the problem: “I think Silicon Valley venture has had a preference for models that don’t involve brick-and-mortar and minimize the use of people; they prefer software businesses,” he said. “The reason we are taking this approach is we know from the research that really well-matched in-person therapy is really effective. Still, at a high level, it’s exciting. There are a lot of people thinking in innovative ways of how we can provide improved mental healthcare.”
Goldcrest Capital also participated in Two Chairs’ Series A.
Powered by WPeMatico
Lack of transparency in healthcare startups risks another Theranos implosion
Are more Theranos -style scandals looming for investors in healthcare startups?
A team of researchers associated with the Meta-Research Innovation Center at Stanford thinks so. They’ve published a paper warning investors in life sciences startups that a systemic lack of transparency exists in their portfolio companies — creating the possibility for more multi-billion-dollar implosions and scandals like the one that toppled Theranos and its charismatic founder, Elizabeth Holmes.
Indeed, one of the study’s authors, Dr. John Ioannidis, the co-director of the Meta-Research Innovation Center at Stanford and director of the University’s PhD program in Epidemiology and Clinical Research, was among the first people to identify the risks associated with Theranos and its “stealth research.”
Now Dr. Ioannidis and his co-authors, Ioana A. Cristea and Eli M. Cahan, have published a study surveying the publicly available research from the largest privately held companies in the healthcare space, and found them lacking.
Most of the highest-valued startups in healthcare have not published any significant scientific literature, the study found. Nearly half of the publications from companies worth more than $1 billion came from only two startups — 23andMe and Adaptive Biotechnologies, according to the paper.
“Many years ago I was the first person to say that Theranos had a problem,” says Ioannidis. “The problem that I had then was that Theranos did not have any peer-reviewed evidence to show.”
In an interview and in their paper, Ioannidis and Cahan warn that investors have overlooked systemic problems created by the lack of transparency among healthcare startups.
They write:
It would be tempting to dismiss the Theranos case as just one rotten apple. However, we worry that the focus on fraud puts aside a more fundamental concern. Fraud is making waves in the news, but stealth research may have a more detrimental impact.
According to the study’s findings, more than half of the healthcare startups that are worth more than $1 billion have published no highly cited papers at all. For companies that were acquired or are publicly traded that number is around 40 percent.
In all, healthcare startups that are currently valued at more than $1 billion published 425 Pubmed papers. And of those papers only 34 (8 percent, including two reviews) were highly cited. For companies with valuations of more than $1 billion that had been acquired or are publicly traded on stock exchanges, the researchers counted 413 papers, of which 47 (11 percent, including nine reviews) were highly cited.
Digging deeper into some of the companies that had high valuations but little or no published research revealed scores of operational and technological issues for the researchers.
For instance, StemCentrx, which was bought for $10.2 billion in 2016 by AbbVie, had published 16 papers — and only one highly cited paper. Since the acquisition, the Food and Drug Administration had imposed a delay on the readout of the company’s phase II trial for its Rova T targeted antibody drug for cancer treatment. In December, a Phase III trial for Rova T as a second-line treatment for patients with advanced small cell lung cancer was halted because the treatment wasn’t working, according to a report in Targeted Oncology.
Acerta Pharma, another healthcare-focused startup focused on cancer treatments, was bought by AstraZeneca for $7.3 billion. That company published nine articles and had one highly cited paper for a very early study of a potential treatment for relapsed chronic lymphocytic leukemia. Acerta received accelerated approval for a drug called acalabrutinib, which treats a rare form of lymphoma called mantle cell lymphoma. Two years ago, AstraZeneca had to retract data and admit that Acerta falsified preclinical data for its drug.
Then there’s Intarcia, the developer of a device for diabetes treatment that’s worth $5.5 billion. That company had its device rejected by the FDA and was forced to lay off staff and halt a couple of later-stage trials. It had only published six papers — none of them very highly cited.
Ultimately, the researchers concluded that highly valued healthcare startups don’t contribute to published research and that the valuation of these companies by investors is divorced from any externally validated data.
For the researchers (and for investors) this should present a problem.
“Many unicorns may be overvalued [21] and subject to unrealistic scientific expectations,” the study’s authors write. And they reject the argument that simply applying for — and receiving — patents is enough to prove that a technology in the healthcare space has been thoroughly vetted. “[Patents] do not offer the same level of documentation as peer-reviewed articles. For example, Theranos had over 100 patents [1], but these were unable to supplant the vacuum in their evidence,” the researchers wrote.
Even if companies want to protect their technology, there are still ways for them to be more transparent about the results or benefits of their technology. The authors acknowledge that publishing isn’t the primary mission of startups. They can, however publish a few high-value articles, secure their technology through patents and then work with researchers, universities or hospitals to validate the technology and have those organizations publish results of the tests, the authors argue.
As the authors conclude:
Start-ups are key purveyors of innovation and disruption. Consequently, holding them to a minimal standard of evaluation from the scientific community is crucial. Participation in peer review, with all its limitations, is the best way we have to uphold this standard. We are not arguing that start-ups should divert excessive resources to having peer-reviewed papers. However, when their products are destined to affect patient health, they should neither be solely doing marketing. Confidential data sharing with potential investors or regulators cannot replace more open scrutiny by the scientific community.
Powered by WPeMatico
Driving down the cost of preserving genetic material, Acorn Biolabs raises $3.3 million
Acorn Biolabs wants consumers to pay them to store genetic material in a bet that the increasing advances in targeted genetic therapies will yield better healthcare results down the line.
The company’s pitch is to “Save young cells today, live a longer, better, tomorrow.” It’s a gamble on the frontiers of healthcare technology that has managed to net the company $3.3 million in seed financing from some of Canada’s busiest investors.
For the Toronto-based company, the pitch isn’t just around banking genetic material — a practice that’s been around for years — it’s about making that process cheaper and easier.
Acorn has come up with a way to collect and preserve the genetic material contained in hair follicles, giving its customers a way to collect full-genome information at home rather than having to come in to a facility and getting bone marrow drawn (the practice at one of its competitors, Forever Labs) .
“We have developed a proprietary media that cells are submerged in that maintains the viability of those cells as they’re being transported to our labs for processing,” says Acorn Biolabs chief executive Dr. Drew Taylor.
“Rapid advancements in the therapeutic use of cells, including the ability to grow human tissue sections, cartilage, artificial skin and stem cells, are already being delivered. Entire heart, liver and kidneys are really just around the corner. The urgency around collecting, preserving and banking youthful cells for future use is real and freezing the clock on your cells will ensure you can leverage them later when you need them,” Taylor said in a statement.
Typically, the cost of banking a full genome test is roughly $2,000 to $3,000, and Acorn says they can drop that cost to less than $1,000. Beyond the cost of taking the sample and storing it, Acorn says it will reduce to roughly $100 a year the fees to store such genetic materials.
It’s important to note that healthcare doesn’t cover any of this. It’s a voluntary service for those neurotic enough or concerned enough about the future of healthcare and their potential health.
There’s also no services that Acorn will provide on the back end of the storage… yet.
“What people do need to realize is that there is power with that data that can improve healthcare. Down the road we will be able to use that data to help people collect that data and power studies,” says Taylor.
The $3.3 million the company raised came from Real Ventures, Globalive Technology, Pool Global Partners and Epic Capital Management and other undisclosed investors.
“Until now, any live cell collection solutions have been highly expensive, invasive and often painful, as well as being geographically limited to specialized clinics,” said Anthony Lacavera, founder and chairman at Globalive. “Acorn is an industry-leading example of how technology can bring real innovation to enable future healthcare solutions that will have meaningful impact on people’s wellbeing and longevity, while at the same time — make it easy, affordable and frictionless for everyone.”
Powered by WPeMatico
K Health raises $25M for its AI-powered primary care platform
K Health, the startup providing consumers with an AI-powered primary care platform, has raised $25 million in Series B funding. The round was led by 14W, Comcast Ventures and Mangrove Capital Partners, with participation from Lerer Hippeau, BoxGroup and Max Ventures — all previous investors from the company’s seed or Series A rounds. Other previous investors include Primary Ventures and Bessemer Venture Partners.
Co-founded and led by former Vroom CEO and Wix co-CEO Allon Bloch, K Health (previously Kang Health) looks to equip consumers with a free and easy-to-use application that can provide accurate, personalized, data-driven information about their symptoms and health.
“When your child says their head hurts, you can play doctor for the first two questions or so — where does it hurt? How does it hurt?” Bloch explained in a conversation with TechCrunch. “Then it gets complex really quickly. Are they nauseous or vomiting? Did anything unusual happen? Did you come back from a trip somewhere? Doctors then use differential diagnosis to prove that it’s a tension headache versus other things by ruling out a whole list of chronic or unusual conditions based on their deep knowledge sets.”
K Health’s platform, which currently focuses on primary care, effectively looks to perform a simulation and data-driven version of the differential diagnosis process. On the company’s free mobile app, users spend three-to-four minutes answering an average of 21 questions about their background and the symptoms they’re experiencing.
Using a data set of two billion historical health events over the past 20 years — compiled from doctors’ notes, lab results, hospitalizations, drug statistics and outcome data — K Health is able to compare users to those with similar symptoms and medical histories before zeroing in on a diagnosis.
With its expansive comparative approach, the platform hopes to offer vastly more thorough, precise and user-specific diagnostic information relative to existing consumer alternatives, like WebMD or, what Bloch calls “Dr. Google,” which often produce broad, downright frightening and inaccurate diagnoses.
Ease and efficiency for both consumers and physicians
Users are able to see cases and diagnoses that had symptoms similar to their own, with K Health notifying users with serious conditions when to consider seeking immediate care. (K Health Press Image / K Health / https://www.khealth.ai)
In addition to pure peace of mind, the utility provided to consumers is clear. With more accurate at-home diagnostic information, users are able to make better preventative health decisions, avoid costly and unnecessary trips to in-person care centers or appointments with telehealth providers and engage in constructive conversations with physicians when they do opt for in-person consultations.
K Health isn’t looking to replace doctors, and, in fact, believes its platform can unlock tremendous value for physicians and the broader healthcare system by enabling better resource allocation.
Without access to quality, personalized medical information at home, many defer to in-person doctor visits even when it may not be necessary. And with around one primary care physician per 1,000 people in the U.S., primary care practitioners are subsequently faced with an overwhelming number of patients and are unable to focus on more complex cases that may require more time and resources. The high volume of patients also forces physicians to allocate budgets for support staff to help interact with patients, collect initial background information and perform less-demanding tasks.
K Health believes that by providing an accurate alternative for those with lighter or more trivial symptoms, it can help lower unnecessary in-person visits, reduce costs for practices and allow physicians to focus on complicated, rare or resource-intensive cases, where their expertise can be most useful and where brute machine processing power is less valuable.
The startup is looking to enhance the platform’s symbiotic patient-doctor benefits further in early-2019, when it plans to launch in-app capabilities that allow users to share their AI-driven health conversations directly with physicians, hopefully reducing time spent on information gathering and enabling more-informed treatment.
With K Health’s AI and machine learning capabilities, the platform also gets smarter with every conversation as it captures more outcomes, hopefully enriching the system and becoming more valuable to all parties over time. Initial results seem promising, with K Health currently boasting around 500,000 users, most having joined since this past July.
Using access and affordability to improve global health outcomes
With the latest round, the company has raised a total of $37.5 million since its late-2016 founding. K Health plans to use the capital to ramp up marketing efforts, further refine its product and technology and perform additional research to identify methods for earlier detection and areas outside of primary care where the platform may be valuable.
Longer term, the platform has much broader aspirations of driving better health outcomes, normalizing better preventative health behavior and creating more efficient and affordable global healthcare systems.
The high costs of the American healthcare system and the impacts they have on health behavior has been well-documented. With heavy co-pays, premiums and treatment cost, many avoid primary care altogether or opt for more reactionary treatment, leading to worse health outcomes overall.
Issues seen in the American healthcare system are also observable in many emerging market countries with less medical infrastructure. According to the World Health Organization, the international standard for the number of citizens per primary care physician is one for every 1,500 to 2,000 people, with some countries facing much steeper gaps — such as China, where there is only one primary care doctor for every 6,666.
The startup hopes it can help limit the immense costs associated with emerging countries educating millions of doctors for eight-to-10 years and help provide more efficient and accessible healthcare systems much more quickly.
By reducing primary care costs for consumers and operating costs for medical practices, while creating a more convenient diagnostic experience, K Health believes it can improve access to information, ultimately driving earlier detection and better health outcomes for consumers everywhere.
Powered by WPeMatico
Keeps parent company Thirty Madison raises $15 million to fight male pattern baldness
Thirty Madison, the healthcare startup behind the hair loss brand Keeps, has brought in a $15.25 million Series A co-led by Maveron and Northzone.
The company provides a subscription-based online marketplace for men’s hair loss prevention medications Finasteride and Minoxidil. Keeps sells these drugs direct-to-consumer, working with manufacturers to keep the costs low.
On Keeps, a subscription of Minoxidil, an over-the-counter topical treatment often referred to by the brand name Rogaine, is $10 monthly. A subscription to Finasteride, a prescription drug taken daily, is $25 per month.
“It’s an end-to-end platform that is the single best place for guys who are looking to keep their hair,” Thirty Madison co-founder Steven Gutentag told TechCrunch.
Keeps is tapping into a big market. According to the American Hair Loss Association, two-thirds of American men experience some hair loss by the age of 35.
You may have heard of Hims, a venture-backed men’s healthcare company that similarly sells subscriptions to hair loss treatments, as well as oral care, skin care and treatments for erectile dysfunction. Keeps is its smaller competitor. For now, the company is focused solely on haircare, though with the new funds, Thirty Madison plans to launch Cove, a sister brand to Keeps that will provide treatments to migraine sufferers.
The company was founded last year by Gutentag and Demetri Karagas with a plan to develop several digital healthcare brands under the Thirty Madison umbrella.
“Going through this process myself of starting to experience hair loss, I was not sure where to turn,” Gutentag said. “I went online and looked up ‘why am I losing my hair,’ and if you search on Google, really for any medical condition, you usually walk away thinking you’re going to die … I was so fortunate that I got access to this high-quality specialist who could help me with my problem and I was in the position to afford those treatments, but most people don’t get that access.”
Keeps also provide digital access to a network of doctors at a cost of roughly $30 per visit.
TechCrunch’s Connie Loizos wrote last year that “it’s never been a better time to be a man who privately suffers from erectile dysfunction, premature ejaculation or hair loss” because of advances and investments in telemedicine. Since then, even more money has been funneled into the space.
Hims has raised nearly $100 million to date and is rumored to be working on a line of women’s products. Roman, a cloud pharmacy for erectile dysfunction, raised an $88 million Series A last month and is launching a “quit smoking kit.” And Lemonaid Health, which also provides prescriptions to erectile dysfunction medications and more, secured $11 million last year.
Greycroft, Steadfast Venture Capital, First Round, ERA, HillCour and Two River also participated in Thirty Madison’s fundraise, which brings its total raised to date to $22.75 million.
Powered by WPeMatico
With $300M in new funding, Devoted Health launches its Medicare Advantage plan in Florida
Devoted Health, a Waltham, Mass.-based insurance startup, has raised a $300 million Series B and is enrolling to its Medicare Advantage plan members in eight Florida counties.
The company, which helps Medicare beneficiaries access care through its network of physicians and tech-enabled healthcare platform, has raised the funds from lead investor Andreessen Horowitz, Premji Invest and Uprising.
The company declined to disclose its valuation.
Devoted’s founders are brothers Todd and Ed Park — the company’s executive chairman and chief executive officer, respectively. Todd co-founded a pair of now publicly traded companies, Athenahealth, a provider of electronic health record systems, and health benefits platform Castlight Health. He also served as the U.S. chief technology officer during the Obama administration. Ed, for his part, was the chief operating officer of Athenahealth until 2016 and a member of Castlight’s board of directors for several years.
Venrock partners Bryan Roberts — Devoted’s founding investor — and Bob Kocher — its chief medical officer — are also part of the company’s founding team.
The Park brothers have tapped Jeremy Delinsky, the former CTO at Wayfair and Athenahealth, as COO; DJ Patil, a former data scientist at the White House, as its head of technology; and Adam Thackery, the former CFO of Universal American, as its chief financial officer.
Its board includes former Health and Human Services Secretary Kathleen Sebelius and former Senate Majority Leader Bill Frist. As part of the latest round, a16z’s Vijay Pande will join its board, too.
The company says it’s committed to treating its customers as if they were members of its employees’ own families. For Patil, the startup’s head of tech, that’s made the entire process of building Devoted a very emotional one.
“I’ve cried a lot at this company,” Patil told TechCrunch. “You meet these seniors and they’ve done everything right. They’ve worked so incredibly hard their entire lives. They’ve given it their all for the American dream. They’ve paid into this model of healthcare and they deserve better.”
Devoted, which previously raised $69 million across two financing rounds in 2017 from Oak HC/FT, Venrock, F-Prime Capital Partners, Maverick Ventures and Obvious Ventures, has begun enrolling to its Medicare Advantage plan seniors located in Broward, Hillsborough, Miami-Dade, Osceola, Palm Beach, Pinellas, Polk and Seminole counties. It will begin providing care January 1, 2019.
Its long-term goal is to offer insurance plans to seniors nationwide.
“We are responsible for these people’s healthcare, so we need to get it right,” Patil said.
Powered by WPeMatico